AstraZeneca's COVID-19 Antibody Provides Protection For At Least Six Months In High-Risk Individuals

  • AstraZeneca plc AZN shared detailed results from the PROVENT Phase 3 pre-exposure prophylaxis (prevention) trial of Evusheld (tixagevimab and cilgavimab), formerly AZD7442.
  • The data showed that Evusheld reduced the risk of developing symptomatic COVID-19 by 77% in the primary analysis and 83% in the six-month follow-up analysis, compared to placebo. 
  • There were no cases of severe disease or COVID-19-related deaths in the Evusheld group through the six-month follow-up.
  • Related: EMA Recommends Approval Of AstraZeneca's COVID-19 Therapy, Evusheld.
  • Additional pharmacokinetic data showed that Evusheld concentrations remained elevated in serum for six months after administration, supporting that a single dose could provide long-term protection against COVID-19 lasting at least six months.
  • The data were published online today in the New England Journal of Medicine.  
  • In the primary analysis, symptomatic COVID-19 occurred in 8/3441 (0.2%) and 17/1731 (1.0%) participants in the Evusheld and placebo groups.
  • In the extended follow-up analysis, symptomatic COVID-19 occurred in 11/3441 (0.3%) and 31/1731 (1.8%) participants in the Evusheld and placebo groups.
  • Efficacy was generally consistent across participant subgroups, where evaluable.
  • Price Action: AZN shares are up 0.28% at $69.04 during the premarket session on the last check Thursday.

Posted In: BriefsCOVID-19 CoronavirusBiotechNewsHealth CareTop StoriesGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.